美国制药巨头礼来公司宣布,已正式向中国国家药品监督管理局提交了口服GLP-1受体激动剂Orforglipron的上市申请。该药物拟用于治疗2型糖尿病和肥胖症,标志着礼来在代谢疾病治疗领域的重要布局。
作为全球GLP-1赛道的有力竞争者,Orforglipron若获批上市,将与中国本土药企及跨国公司的同类产品展开市场竞争。此次申报也凸显出中国代谢疾病治疗市场的巨大潜力正吸引更多国际创新疗法加速落地。
美国制药巨头礼来公司宣布,已正式向中国国家药品监督管理局提交了口服GLP-1受体激动剂Orforglipron的上市申请。该药物拟用于治疗2型糖尿病和肥胖症,标志着礼来在代谢疾病治疗领域的重要布局。
作为全球GLP-1赛道的有力竞争者,Orforglipron若获批上市,将与中国本土药企及跨国公司的同类产品展开市场竞争。此次申报也凸显出中国代谢疾病治疗市场的巨大潜力正吸引更多国际创新疗法加速落地。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.